Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ursodeoxycholic acid - Alfa Farmaceutici/sanofi-aventis

Next Previous
X
Search
Drug Profile

Ursodeoxycholic acid - Alfa Farmaceutici/sanofi-aventis

Alternative Names: Actigall; Delursan; LJDCA; UDCA; Urso; Urso 500; Urso DS; Urso Forte; Ursobilane; Ursochol; Ursodesoxycholic acid; Ursodiol; Ursolite; Ursosan

Latest Information Update: 05 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfa Farmaceutici; sanofi-aventis
  • Developer AbbVie; Adare Pharmaceuticals; Axcan Pharma; Estedi; Mitsubishi Tanabe Pharma Corporation; Novartis; Procter & Gamble Pharmaceuticals Spain; sanofi-aventis; Zambon Company SpA
  • Class Cholic acids; Gallstone therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Cholesterol inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholelithiasis; Liver disorders; Primary biliary cirrhosis; Primary sclerosing cholangitis
  • No development reported Hypercholesterolaemia; Liver transplant rejection
  • Discontinued Colorectal cancer; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Apr 2021 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
  • 09 Apr 2021 Discontinued - Phase-II/III for Colorectal cancer in USA (PO)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top